Sugi Predict

Sugi Predict / Compounds / SCHEMBL3716490

SCHEMBL3716490

SCHEMBL3716490

Fc1ccc2cnccc2c1Br

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IMPDH2 P12268 5/20 0.61
▸ MAPT P10636 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ LMNA P02545 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ MAPKAPK2 P49137 1/20 0.41
▸ ERN1 O75460 1/20 0.40
▸ LOXL2 Q9Y4K0 1/20 0.38
▸ HTT P42858 2/20 0.38
▸ CDK4 P11802 1/20 0.38
▸ CCND1 P24385 1/20 0.38
▸ AXL P30530 1/20 0.36
▸ PIM1 P11309 2/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CDK9 P50750 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15058583 0.84 IMPDH2 (0.43) IMPDH2MAPTKDM4EALDH1A1LOXL2
SCHEMBL30709993 0.84 IMPDH2 (0.43) IMPDH2MAPTKDM4EALDH1A1LOXL2
SCHEMBL29986726 0.79 IMPDH2 (0.46) IMPDH2MAPTKDM4EALDH1A1LMNA
SCHEMBL19641735 0.76 IMPDH2 (0.52) IMPDH2MAPTKDM4EALDH1A1LMNA
SCHEMBL5655780 0.76 IMPDH2 (0.52) IMPDH2MAPTKDM4EALDH1A1LMNA
SCHEMBL31629068 0.76 IMPDH2 (0.61) IMPDH2MAPTKDM4EALDH1A1LMNA
SCHEMBL1705663 0.76 IMPDH2 (0.61) IMPDH2KDM4ELMNACYP1A2CYP3A4
SCHEMBL31552249 0.76 IMPDH2 (0.61) IMPDH2MAPTKDM4EALDH1A1LMNA
SCHEMBL252216 0.76 IMPDH2 (1.00) IMPDH2KDM4ELMNACYP1A2CYP3A4
SCHEMBL1705034 0.76 IMPDH2 (0.61) IMPDH2MAPTKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115055128-A Preparation method of cyclopropyl-substituted nitrogen-containing six-membered heterocyclic compound 北京六合宁远医药科技股份有限公司 2022-09-16 — — CN claimed
US-12516059-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2026-01-06 — — US disclosed
US-20240383889-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-11-21 — — US disclosed
US-11891388-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2024-02-06 — — US disclosed
US-11542265-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2023-01-03 — — US disclosed
CN-115055128-A Preparation method of cyclopropyl-substituted nitrogen-containing six-membered heterocyclic compound 北京六合宁远医药科技股份有限公司 2022-09-16 — — CN disclosed
US-20220227752-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2022-07-21 — — US disclosed
US-20220081427-A1 INHIBITORS OF JUN N-TERMINAL KINASE IMAGO PHARMACEUTICALS, INC. (US) 2022-03-17 — — US disclosed
US-11242343-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2022-02-08 — — US disclosed
US-20210371425-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-02 — — US disclosed
US-8853203-B2 Diazepinone derivatives NOVARTIS AG (CH) 2014-10-07 — — US disclosed
US-20140057902-A1 Diazepinone derivatives NOVARTIS AG (CH) 2014-02-27 — — US disclosed
US-20140057902-A1 Diazepinone derivatives NOVARTIS AG (CH) 2014-02-27 — — US disclosed
WO-2014030128-A1 DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE NOVARTIS AG (CH) 2014-02-27 — — WO disclosed
US-20140057902-A1 Diazepinone derivatives NOVARTIS AG (CH) 2014-02-27 — — US disclosed
US-8450363-B2 Inhibitors of Jun N-terminal kinase ELAN PHARMACEUTICALS, INC. (US) 2013-05-28 — — US disclosed
US-20130072494-A1 INHIBITORS OF JUN N-TERMINAL KINASE ELAN PHARMACEUTICALS, INC. 2013-03-21 — — US disclosed
EP-2393806-A1 INHIBITORS OF JUN N-TERMINAL KINASE Elan Pharmaceuticals Inc. (US) 2011-12-14 — — EP disclosed
US-20100331335-A1 Inhibitors of Jun N-Terminal Kinase ELAN PHARMACETICALS, INC. 2010-12-30 — — US disclosed
WO-2010091310-A1 INHIBITORS OF JUN N-TERMINAL KINASE ELAN PHARMACEUTICALS, INC. (US) 2010-08-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383889-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 IMPDH2 1418/4885MAPT 4343/4885KDM4E 3818/4885
US-11242343-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 IMPDH2 1418/4885MAPT 4343/4885KDM4E 3818/4885
US-20130072494-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 IMPDH2 4706/4885MAPT 51/4885KDM4E 1237/4885
US-20140057902-A1 Diazepinone derivatives ADRB1, ADRB2, BRD4 IMPDH2 1127/4885MAPT 1174/4885KDM4E 1438/4885
US-20220227752-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 IMPDH2 1418/4885MAPT 4343/4885KDM4E 3818/4885
US-11542265-B2 Pyrazolopyrimidine compounds and uses thereof PDXK, PCK1, PDK2 IMPDH2 1103/4885MAPT 4245/4885KDM4E 3528/4885
US-11891388-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 IMPDH2 1418/4885MAPT 4343/4885KDM4E 3818/4885
US-20220081427-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 IMPDH2 4706/4885MAPT 51/4885KDM4E 1237/4885
US-20210371425-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PDK2 IMPDH2 1103/4885MAPT 4245/4885KDM4E 3528/4885
US-20100331335-A1 Inhibitors of Jun N-Terminal Kinase CHUK, MAPK6, MAPK3 IMPDH2 4706/4885MAPT 51/4885KDM4E 1237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.